Telix Pharmaceuticals saw its shares climb sharply on Tuesday, rising 10.3% to A$18.03 as investors reacted to a U.S. Food and Drug Administration approval and encouraging company results. The stock extended its gains after the agency approved Pixclara, the company’s amino acid PET imaging agent formally named floretyrosine F 18.
The FDA authorization, announced on Monday, covers Pixclara for use in differentiating recurrent or progressive glioma from treatment-related changes in patients. That regulatory clearance makes Telix the sole company with an FDA-approved radiopharmaceutical imaging agent for this specific indication.
Clinically and commercially, the indication addresses a meaningful slice of neuro-oncology. The company notes that gliomas make up about 30% of all brain and central nervous system tumors and represent roughly 80% of malignant brain tumors, highlighting the scale of the potential addressable population for an approved diagnostic agent.
Investor attention was further amplified by Telix’s managerial presence at the H.C. Wainwright 28th Annual Global Investment Conference in New York. Managing Director and Group CEO Dr. Christian Behrenbruch, together with Precision Medicine CEO Kevin Richardson, presented on September 15, giving the company a direct forum to discuss the Pixclara approval and the broader pipeline with institutional investors.
Market enthusiasm was also backed by Telix’s recent operating performance. For the first half of 2026, group revenue reached US$477 million, a year-over-year increase of 22%, while adjusted EBITDA rose by 146%. Management has updated its full-year outlook, raising guidance to target total revenue and other income in excess of US$1 billion.
The share move came despite weakness in the wider Australian market; Telix climbed while the S&P/ASX 200 index fell 0.9% on the day. The combination of exclusive FDA approval in this imaging indication, visible commercial scale implied by glioma epidemiology, a clear financial uplift in H1 2026, and a management presentation at a major investor conference together helped to consolidate buyer conviction.
Summary: FDA approval of Pixclara (floretyrosine F 18) for imaging recurrent or progressive glioma, strong H1 2026 financials and a high-profile investor presentation drove a 10.3% rise in Telix shares to A$18.03 on Tuesday.
Key points:
- Regulatory milestone - Pixclara approved by the U.S. FDA for differentiating recurrent or progressive glioma from treatment-related changes.
- Commercial scale - Gliomas account for about 30% of brain and CNS tumors and around 80% of malignant brain tumors, indicating a sizable target population for the approved imaging agent.
- Financial momentum - H1 2026 group revenue of US$477 million (up 22% year-over-year), adjusted EBITDA up 146%, and upgraded full-year guidance to exceed US$1 billion in total revenue and other income.
Risks and uncertainties:
- Market concentration - The stock’s move was tied to a single regulatory approval in a specific imaging indication; broader commercial uptake will determine sustained revenue impact.
- Execution and commercialization - Realizing the potential implied by glioma prevalence depends on successful market roll-out and adoption by clinicians and payers.
- Market context - Telix’s share gains occurred while the S&P/ASX 200 index declined 0.9%, underscoring broader market volatility that could influence stock performance.